BTIG Research Forecasts Strong Price Appreciation for Haemonetics (NYSE:HAE) Stock

Haemonetics (NYSE:HAE) had its target price hoisted by investment analysts at BTIG Research from $130.00 to $142.00 in a note issued to investors on Thursday, Benzinga reports. The firm presently has a “buy” rating on the medical instruments supplier’s stock. BTIG Research‘s price target indicates a potential upside of 14.34% from the company’s current price.

Other analysts have also issued research reports about the company. Weiss Ratings raised Haemonetics from a “hold (c-)” rating to a “hold (c)” rating in a report on Tuesday, August 11th. Robert W. Baird increased their target price on Haemonetics from $96.00 to $119.00 and gave the company an “outperform” rating in a report on Friday, August 21st. JPMorgan Chase & Co. raised their target price on Haemonetics from $62.00 to $86.00 and gave the stock a “neutral” rating in a research report on Friday, August 7th. Raymond James Financial boosted their price target on Haemonetics from $105.00 to $125.00 and gave the company an “outperform” rating in a research note on Thursday, September 3rd. Finally, Mizuho upped their price target on shares of Haemonetics from $95.00 to $140.00 and gave the company an “outperform” rating in a research report on Friday, October 9th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, Haemonetics currently has a consensus rating of “Moderate Buy” and a consensus target price of $111.33.

Haemonetics Stock Performance

HAE stock traded down $3.23 on Thursday, hitting $124.19. The company had a trading volume of 413,083 shares, compared to its average volume of 807,345. Haemonetics has a 12-month low of $51.00 and a 12-month high of $132.00. The company has a current ratio of 3.08, a quick ratio of 1.91 and a debt-to-equity ratio of 1.40. The stock’s 50-day simple moving average is $110.86 and its 200 day simple moving average is $79.55. The stock has a market cap of $5.65 billion, a price-to-earnings ratio of 60.16, a P/E/G ratio of 2.40 and a beta of 0.63.

Haemonetics (NYSE:HAE) last announced its earnings results on Thursday, November 5th. The medical instruments supplier reported $1.35 earnings per share for the quarter, beating analysts’ consensus estimates of $1.29 by $0.06. The business had revenue of $357.76 million during the quarter, compared to analyst estimates of $345.15 million. Haemonetics had a net margin of 7.12% and a return on equity of 27.55%. The company’s quarterly revenue was up 9.4% compared to the same quarter last year. During the same period in the previous year, the business earned $1.27 EPS. As a group, equities research analysts expect that Haemonetics will post 5.29 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Haemonetics

Several hedge funds and other institutional investors have recently modified their holdings of HAE. Fortitude Family Office LLC raised its holdings in Haemonetics by 104.5% in the 3rd quarter. Fortitude Family Office LLC now owns 272 shares of the medical instruments supplier’s stock worth $29,000 after purchasing an additional 139 shares during the period. Root Financial Partners LLC bought a new stake in Haemonetics during the third quarter valued at about $40,000. Kelleher Financial Advisors bought a new stake in Haemonetics during the second quarter valued at about $38,000. Northwestern Mutual Wealth Management Co. bought a new stake in Haemonetics during the second quarter valued at about $44,000. Finally, Public Employees Retirement System of Ohio purchased a new stake in Haemonetics in the second quarter worth about $54,000. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Haemonetics

Here are the key news stories impacting Haemonetics this week:

• Positive Sentiment: Fiscal Q2 earnings were $1.35 per share, above the $1.29 analyst consensus and up from $1.27 a year earlier. Revenue rose 9.4% year over year to $357.8 million, topping the $345.1 million estimate. Haemonetics reports Q2 results
• Positive Sentiment: Haemonetics raised its fiscal 2027 revenue and organic-growth outlook following the quarter, signaling management sees continued growth. Haemonetics raises FY27 revenue outlook
• Neutral Sentiment: The stock recently reached a 52-week high, and its elevated valuation may heighten expectations or encourage some investors to take profits. The available reports do not establish this as the cause of the share decline. Haemonetics hits a fresh high

Haemonetics Company Profile

Haemonetics Corporation (NYSE: HAE) is a healthcare technology company that develops and supplies products and services for blood and plasma collection, processing, and management. Its solutions are used by blood and plasma collection organizations, hospitals, and other healthcare providers to support the efficient handling of blood components and improve patient care.

The company’s offerings include automated plasma and blood-component collection systems, disposable collection sets, blood-processing equipment, and software designed to manage collection and transfusion-related operations.